One in eight American adults now takes a GLP-1 drug. That is up from roughly one in fifty just five years ago. The numbers come from Epic Research, which launched a quarterly tracker this June and found that GLP-1 prescriptions climbed from one thousand eight hundred eighty-four per hundred thousand patients in mid-2021 to eight thousand eight hundred nineteen in early 2026. That is a more than fourfold increase, driven almost entirely by semaglutide and tirzepatide.
But just as usage hits this extraordinary peak, new data is exposing what happens when patients stop. And the picture is sobering.
The Rise No One Predicted
When semaglutide won FDA approval for chronic weight management in 2021, few analysts projected the scale of what followed. Tirzepatide followed in 2023. Together they reshaped not just diabetes and obesity care but the entire pharmaceutical landscape. Novo Nordisk and Eli Lilly became two of the most valuable companies on earth. Supply shortages became routine. Compounding pharmacies built entire business lines around GLP-1 copies.
Epic Research now provides hard numbers to quantify the trend. Their data covers more than two hundred million anonymized patient records across the United States. The GLP-1 utilization tracker shows prescriptions growing steadily across both diabetic and non-diabetic populations. The share of U.S. adults classified as obese declined modestly over the same period, from forty-two point three percent to forty point seven percent. That shift represents millions of people moving into a healthier weight category.
So the drugs work. The question now is what happens when people stop taking them.
The WashU Study: Twenty-Two Percent Higher Risk
Researchers at Washington University School of Medicine in St. Louis followed more than three hundred thirty-three thousand U.S. veterans with type 2 diabetes over three years. All had been prescribed GLP-1 drugs. Some continued. Some stopped or interrupted treatment.
The results, published in BMJ Medicine, found that stopping GLP-1 treatment for as little as six months was linked to a significant increase in the risk of major cardiovascular events. Heart attack. Stroke. Death. The longer the treatment gap, the bigger the jump. After two years off GLP-1 drugs, patients faced a twenty-two percent higher risk of major cardiovascular events compared to those who stayed on treatment.
“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop,” said senior author Ziyad Al-Aly, a WashU Medicine clinical epidemiologist. “Many quit after a few months because of cost, side effects or shortages. When they stop, it is not just weight that comes back. They experience a resurgence in inflammation, blood pressure, and cholesterol. Weight regain is visible. The metabolic reversal is not.”
This is the hidden cost embedded in the GLP-1 revolution. The drugs produce remarkable results but only for as long as people keep taking them. And keeping people on them is proving difficult. A separate study from ScienceDaily found that most people who stop GLP-1 drugs eventually return to them, creating a cycle of stop-start treatment that the WashU data suggests may carry its own cardiovascular penalties.
The Cancer Connection
Amid the cautionary data from WashU, another finding is generating attention. Researchers are now investigating whether GLP-1 drugs may protect against cancer. NPR reported in June that multiple studies have observed lower cancer rates among GLP-1 users, and scientists are working to understand the mechanism. The leading hypothesis involves the drugs’ anti-inflammatory effects and their ability to reduce obesity, a known cancer risk factor.
If confirmed, this would add another layer to the already complex calculus around GLP-1 therapy. The benefits accumulate with continued use. But the WashU study makes clear that these benefits are not permanent. They are rented, not owned.
What Experienced Teams Know
Here is the anti-pattern that most market observers miss. The GLP-1 business model assumes chronic, lifelong therapy. That is what makes the revenue projections work. But real-world adherence data tells a different story. Cost is the number one barrier. At roughly a thousand dollars per month out of pocket for weight loss indications, many patients simply cannot sustain treatment. Side effects drive others away. Supply shortages force interruptions.
The WashU study reveals that these interruptions are not neutral. Each treatment gap creates a window of elevated cardiovascular risk. Over time, the cumulative effect may largely erase the protection gained while on the drug. This has profound implications for how payers, providers, and manufacturers think about GLP-1 access. A therapy that only works when taken continuously is a therapy that demands continuous coverage.
Experienced clinical teams are already adapting. Some are tapering patients to lower maintenance doses rather than stopping entirely. Others are using combination approaches with cheaper generic alternatives to bridge gaps. But these are workarounds, not a systemic solution.
So where does this leave us? The Epic Research data confirms that GLP-1 drugs have achieved mass adoption faster than almost any drug class in history. The WashU data warns that the consequences of interrupted treatment extend well beyond weight regain into life-threatening cardiovascular territory. And the cancer protection research suggests the benefits may be even broader than initially understood.
These three threads together point toward an inevitable conclusion. GLP-1 drugs work. They work for multiple conditions. But they require sustained, uninterrupted access to deliver their full benefit. That access question, more than any single clinical data point, will define the next chapter of the GLP-1 story.
Something to watch.
Further Reading
- Retatrutide Hits 30% Weight Loss in Pivotal Phase 3 Trial
- GLP-1 Weight Loss Drugs Shed 28% Lean Mass — 36-Trial Meta-Analysis
- When Will Oral Peptides Replace Injectables? A Realistic Assessment
Last reviewed: June 2026. Peptide Proof Editorial Team. Sources: Epic Research, WashU Medicine, NPR
